Influence of astragaloside IV on pharmacokinetics of triptolide in rats and its potential mechanism

Gao, Jian; Zeng, Xiangmin; Zhao, Wei; Chen, Desheng; Liu, Jing; Zhang, Ning; Duan, Xingliang

doi:10.1080/13880209.2019.1702705

Cited by 8 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the one hand, Exo could deliver TP into tumor tissue via the EPR effect, and cRGD-Exo/TP was endowed with higher tumor-targeting ability after being engineered with cRGD, further enhancing the interaction with tumor cells. On the other hand, TP might be effluxed by the P-glycoprotein (P-gp) of A375 cells [ 46 , 47 ]. The results were consistent with those of cell uptake.…”

Section: Resultsmentioning

confidence: 99%

αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma

Jiang

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

Background Melanoma is the most malignant skin tumor and is difficult to cure with the alternative treatments of chemotherapy, biotherapy, and immunotherapy. Our previous study showed that triptolide (TP) exhibited powerful tumoricidal activity against melanoma. However, the clinical potential of TP is plagued by its poor aqueous solubility, short half-life, and biotoxicity. Therefore, developing an ideal vehicle to efficiently load TP and achieving targeted delivery to melanoma is a prospective approach for making full use of its antitumor efficacy. Results We applied exosome (Exo) derived from human umbilical cord mesenchymal stromal cells (hUCMSCs) and engineered them exogenously with a cyclic peptide, arginine-glycine-aspartate (cRGD), to encapsulate TP to establish a bionic-targeted drug delivery system (cRGD-Exo/TP), achieving synergism and toxicity reduction. The average size of cRGD-Exo/TP was 157.34 ± 6.21 nm, with a high drug loading of 10.76 ± 1.21%. The in vitro antitumor results showed that the designed Exo delivery platform could be effectively taken up by targeted cells and performed significantly in antiproliferation, anti-invasion, and proapoptotic activities in A375 cells via the caspase cascade and mitochondrial pathways and cell cycle alteration. Furthermore, the biodistribution and pharmacokinetics results demonstrated that cRGD-Exo/TP possessed superior tumor targetability and prolonged the half-life of TP. Notably, cRGD-Exo/TP significantly inhibited tumor growth and extended survival time with negligible systemic toxicity in tumor-bearing mice. Conclusion The results indicated that the functionalized Exo platform provides a promising strategy for targeted therapy of malignant melanoma. Graphical Abstract

show abstract

Section: Resultsmentioning

confidence: 99%

αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma

Jiang

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…These characteristics suggest that puerarin can significantly change the pharmacokinetic characteristics of AS-IV by increasing the absorption of AS-IV or inhibiting its metabolism in Frontiers in Pharmacology frontiersin.org vivo (Zhang et al, 2020). Other TCM components, such as triptolide (Gao et al, 2020), cycloastragenol (He et al, 2018), atractylenolide I (Song et al, 2014), and prim-O-glucosylcimifugin (Song et al, 2014), can also change the pharmacokinetic characteristics of AS-IV. Drugs play an important role in the identification of metabolites in vivo, and a systematic study of AS-IV metabolism in vivo can aid in determining its pharmacological mechanism.…”

Section: Pharmackinetics Of As-ivmentioning

confidence: 99%

Astragaloside IV, as a potential anticancer agent

Xia

Li²,

Tang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer is a global intractable disease, and its morbidity and mortality are increasing year by year in developing countries. Surgery and chemotherapy are often used to treat cancer, but they result in unsatisfactory outcomes, such as severe side effects and drug resistance. With the accelerated modernization of traditional Chinese medicine (TCM), an increasing body of evidence has shown that several TCM components have significant anticancer activities. Astragaloside IV (AS-IV) is considered the main active ingredient of the dried root of Astragalus membranaceus. AS-IV exhibits various pharmacological effects, such as anti-inflammatory, hypoglycemic, antifibrotic, and anticancer activities. AS-IV possesses a wide range of activities, such as the modulation of reactive oxygen species-scavenging enzyme activities, participation in cell cycle arrest, induction of apoptosis and autophagy, and suppression of cancer cell proliferation, invasiveness, and metastasis. These effects are involved in the inhibition of different malignant tumors, such as lung, liver, breast, and gastric cancers. This article reviews the bioavailability, anticancer activity, and mechanism of AS-IV and provides suggestions for further research of this TCM.

show abstract

Determination of vericiguat in rat plasma by UPLC-MS/MS and its application to drug interaction

Ding,

Guo,

Fang

et al. 2023

Journal of Chromatography A

View full text Add to dashboard Cite

Influence of astragaloside IV on pharmacokinetics of triptolide in rats and its potential mechanism

Cited by 8 publications

References 19 publications

αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma

αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma

Astragaloside IV, as a potential anticancer agent

Determination of vericiguat in rat plasma by UPLC-MS/MS and its application to drug interaction

Contact Info

Product

Resources

About